期刊文献+

LC-MS/MS法测定全血中西罗莫司的药物浓度 被引量:3

LC-MS/MS determination of sirolimus in human whole blood
原文传递
导出
摘要 目的建立测定人全血中西罗莫司(免疫抑制剂)浓度的LC-MS/MS的方法。方法全血样品经硫酸锌乙腈混合液沉淀后,用Zobox XDB-CN色谱柱,0.1 mmol.L-1乙酸水-0.1 mmol.L-1乙酸乙腈(60∶40)为流动相,流速0.45 mL.min-1,通过电喷雾离子化电离源,经多反应监测模式检测。结果全血中西罗莫司的线性范围为1.12~33.47μg.L-1,日内、日间RSD均小于10%,提取回收率为81.4%~92.4%。结论本法灵敏、准确、快速,可用于人全血中西罗莫司浓度监测和药代动力学研究。 Objective To establish a LC - MS/MS method for determination of sirolimus in human whole blood. Methods The samples of whole blood were deproteinated by ZeSO4 - aeetonitrile mixed liquid and separated by a Zobox XDB - CN column with a mobile plase of water - aeetonitrile solution (containing 0. 1 mmol · L-1 acetic acid, 60: 40) at the flow rate of 0. 45 mL · min-1 Detection was performed on a tandem mass spectrometry with electrospray ionization source in positive ion mode. Multiple reactions monitoring mode was used to quantify sirolimus and internal standard respectively. Results The linear range of siroli- mus was 1.12 - 33.47 μg · L-1. The intra - day and inter - day RSD were both less than 10%. The extraction recoveries were 81.4% - 92. 4%. Conclusion The method is sensitive, accurate and simple for monitoring of whole blood concentration of sirolimus.
出处 《中国临床药理学杂志》 CAS CSCD 北大核心 2012年第4期292-294,共3页 The Chinese Journal of Clinical Pharmacology
关键词 西罗莫司 液相色谱质谱联用 血药浓度 sirolimus LC - MS/MS blood concentration
  • 相关文献

参考文献4

二级参考文献41

  • 1HARDMAN J G, LIMBIRD L E. Goodman & Gilman'S Pharmacological Basis of Therapeutics(古德曼·吉德曼 治疗学的药理学基础) [M]. Tenth Edition Beljing: People's medical publishing House, 2002:1339.
  • 2VICENTE F B, SMITH F A, PENG Y,et al. Evaluatian of an immunoassay of whole blood sirolimus in pediatric transplant patients in comparison with high-performance liquid chromatugraphy/tandem mass spectrometry [ J ]. Clin Chem Lab Med, 2006,44 ( 4 ) :497 -499.
  • 3BORROWS R, CHUSNEY G, LOUCAIDOU M, et al. Tacrolimus monitoring in renal transplantation: a comparison between high- performance liquid chromatography and immunoassay [ J ] .Transplant Proc,2005,37(4) :1733-1735.
  • 4SALM P, TAYLOR P J, LYNCH S V, et al. A rapid HPLC-mass spectrometry cyclosporln method suitable for current monitoring practices [ J ]. Clin Biochem,2005,38 ( 7 ) :667-673.
  • 5RAYMOND G M. Immunosuppressant drag monitoring: is the labortary meeting clinical expections? [ J ]. Transplantation ,2005, 39(1) :119-127.
  • 6Morales JM, Wramner L, Kreis H, et al. Sirolimus does not exhibit nephrotoxicity compared to cyclosporine in renal transplant recipients[J]. Am J Transplant,2002,2(5) :436-442.
  • 7Sehgal SN, Rapamune (RAPA, rapamycin, sirolimus): mechanism of action immunosuppressive effect results from blockade of signal transduction and inhibition of cell cycle progression [J]. Clin Biochem,2006,39(5):484-489.
  • 8Fung J, Kelly D, Kadry Z, et al. Immunosuppression in liver transplantation: beyond ca|cineurin inhibitors[J]. Liver Transpl, 2005 : 11 (3) : 267-280.
  • 9Soliman GA. The mammalian target of rapamycin signaling network and gene regulation [J]. Curr Opin Lipidol,2005,16(3): 317-323.
  • 10Vignot S, Faivre S, Aguirre D, et al. roTOR-targeted therapy of cancer with rapamycin derivatives[J]. Ann Oncol,2005,16 (4) : 525-537.

共引文献16

同被引文献17

引证文献3

二级引证文献5

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部